Skip to main content
SpringerLink
Log in

Myeloid neoplasm with isolated del(5q) and the MPLW515L mutation fulfills the WHO diagnostic criteria for ET

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

A 70-year-old male was referred to our hospital for marked thrombocytosis without anemia. The patient simultaneously presented with an MPL W515L mutation, one of the major driver mutations in essential thrombocythemia (ET), and deletion of 5q, a characteristic cytogenetic abnormality in myelodysplastic syndrome (MDS). Bone marrow examination showed a combination of both mature hyperlobulated megakaryocytes, as found in ET, and small hypolobulated megakaryocytes, typically found in MDS with del(5q). The present case is consistent with the recently proposed category of myeloid neoplasms with isolated del(5q) and an MPN driver mutation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–79. https://doi.org/10.1182/blood-2016-10-695940.

    Article  CAS  PubMed  Google Scholar 

  2. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016;91(1):76–89. https://doi.org/10.1002/ajh.24253.

    Article  CAS  PubMed  Google Scholar 

  3. Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow [14]. Leukemia. 2006;20(7):1319–21. https://doi.org/10.1038/sj.leu.2404215.

    Article  CAS  PubMed  Google Scholar 

  4. Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, et al. Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol. 2011;86(5):393–8. https://doi.org/10.1002/ajh.21984.

    Article  CAS  PubMed  Google Scholar 

  5. Meggendorfer M, Haferlach C, Kern W, Haferlach T. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. Haematologica. 2017;102(9):1502–10. https://doi.org/10.3324/haematol.2017.166173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Geyer JT, Verma S, Mathew S, Wang YL, Racchumi J, Espinal-Witter R, et al. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Hum Pathol. 2013;44(3):346–56. https://doi.org/10.1016/j.humpath.2012.05.022.

    Article  CAS  PubMed  Google Scholar 

  7. Sangiorgio VFI, Geyer JT, Margolskee E, Al- Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a grey zone combination of myelodysplastic and myeloproliferative features? Haematologica. 2019. https://doi.org/10.3324/haematol.2019.227686.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wong KF, Yu PH, Wong WS. Essential thrombocythemia with deleted 5q - a genetic and morphologic hybrid? Cancer Genet Cytogenet. 2010;201(1):39–41. https://doi.org/10.1016/j.cancergencyto.2010.04.019.

    Article  CAS  PubMed  Google Scholar 

  9. Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res. 2010;34(6):821–3. https://doi.org/10.1016/j.leukres.2009.09.016.

    Article  CAS  PubMed  Google Scholar 

  10. Alshaban A, Padilla O, Philipovskiy A, Corral J, McAlice M, Gaur S. Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome. Leuk Res Rep. 2018;10:37–40. https://doi.org/10.1016/j.lrr.2018.08.001.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, et al. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol. 2009;90(4):522–5. https://doi.org/10.1007/s12185-009-0411-5.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207–9. https://doi.org/10.1182/blood-2005-03-1183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, et al. WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2. MPL and IDH Mutations Leuk. 2010;24(7):1283–9. https://doi.org/10.1038/leu.2010.105.

    Article  CAS  Google Scholar 

  14. Azaceta G, Calasanz MJ, Dourdil V, Bonafonte E, Izquierdo I, Palomera L. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. Leuk Lymph. 2010;51(10):1941–3. https://doi.org/10.3109/10428194.2010.506567.

    Article  CAS  Google Scholar 

  15. Nomdedeu M, Maffioli M, Calvo X, Martínez-Trillos A, Baumann T, Díaz-Beyá M, et al. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leuk Res. 2011;35(9):1276–8. https://doi.org/10.1016/j.leukres.2011.06.008.

    Article  PubMed  Google Scholar 

  16. Musto P, Simeon V, Guariglia R, Bianchino G, Grieco V, Nozza F, et al. Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. OncoTargets Ther. 2014;7:1043–50. https://doi.org/10.2147/OTT.S59628.

    Article  CAS  Google Scholar 

  17. Hatzimichael E, Lagos K, Vassou A, Gougopoulou D, Papoudou-Bai A, Briasoulis E. Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment. Mol Clin Oncol. 2016;5(1):23–6. https://doi.org/10.3892/mco.2016.866.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Oka S, Ono K, Nohgawa M. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide. Leuk Lymph. 2017;58(10):2511–3. https://doi.org/10.1080/10428194.2017.1295146.

    Article  CAS  Google Scholar 

  19. Tremblay-LeMay R, Chang H. Concurrent JAK2 mutation and isolated del(5q) associated with marrow fibrosis and small hypo/monolobated megakaryocytes. Blood. 2018;132(1):112. https://doi.org/10.1182/blood-2018-03-842161.

    Article  CAS  PubMed  Google Scholar 

  20. Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, et al. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Ann Hematol. 2019;98(2):331–7. https://doi.org/10.1007/s00277-018-3509-0.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi-ken, 409-3898, Japan

    Keita Kirito

Authors
  1. Keita Kirito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keita Kirito.

Ethics declarations

Conflict of interest

The author declares that he has no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient for the diagnostic and treatment procedures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kirito, K. Myeloid neoplasm with isolated del(5q) and the MPLW515L mutation fulfills the WHO diagnostic criteria for ET. Int J Hematol 112, 238–242 (2020). https://doi.org/10.1007/s12185-020-02872-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-02872-3

Keywords

Search

Navigation